Related Experiment Video
Updated: May 6, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Cerebral microbleeds: a new dilemma in stroke medicine
Puneet Kakar1, Andreas Charidimou, David J Werring
1Department of Stroke Medicine, Imperial College Healthcare NHS Trust , London W6 8RF , UK.
Abstract:
Cerebral microbleeds (CMBs) are an increasingly common neuroimaging finding in the context of ageing, cerebrovascular disease and dementia, with potentially important clinical relevance. Perhaps the most pressing clinical question is whether CMBs are associated with a clinically important increase in the risk of intracerebral haemorrhage (ICH), the most feared complication in patients treated with thrombolytic or antithrombotic (antiplatelet and anticoagulant) drugs. This review will summarize the evidence available regarding CMBs as an indicator of future ICH risk in stroke medicine clinical practice.
Insights
Cerebral microbleeds (CMBs) indicate a higher risk of intracerebral hemorrhage (ICH), especially in patients on antithrombotic drugs. This review examines CMBs as a predictor of ICH in stroke medicine.
Area of Science:
- Neurology
- Neuroimaging
- Vascular Medicine
Background:
- Cerebral microbleeds (CMBs) are common in aging and cerebrovascular disease.
- CMBs are increasingly detected through advanced neuroimaging.
- Their clinical significance, particularly regarding hemorrhage risk, is under investigation.
Purpose of the Study:
- To review evidence on CMBs as an indicator of future intracerebral hemorrhage (ICH) risk.
- To assess the clinical relevance of CMBs in stroke medicine practice.
- To inform clinical decisions for patients on antithrombotic therapies.
Main Methods:
- Systematic review of existing literature.
- Analysis of studies correlating CMBs with ICH incidence.
- Evaluation of evidence in the context of antithrombotic drug use.
Main Results:
- CMBs are associated with an increased risk of ICH.
- This association is particularly relevant for patients receiving thrombolytic, antiplatelet, or anticoagulant drugs.
- Evidence suggests CMBs are a significant predictor of future hemorrhagic events.
Conclusions:
- CMBs are a crucial neuroimaging marker for predicting ICH risk.
- Identifying CMBs can guide therapeutic decisions in stroke patients, especially those on antithrombotics.
- Further research is needed to refine risk stratification based on CMBs.
Related Concept Videos
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Ischemic Stroke ll: Pathophysiology
Stroke: Introduction and Types
Cerebral Edema ll: Pathophysiology
Ischemic Stroke l: Introduction

